Mr Helfgott joined Novo Nordisk in April 2019 as executive vice president of Rare Disease.

(Not registered as an executive of Novo Nordisk A/S with the Danish Business Authority)

Mr Helfgott joined Novo Nordisk from AstraZeneca, UK, where he was global vice president in charge of the company's cardiovascular, metabolism and renal global franchise, supervising both assets in development and on the market. He joined AstraZeneca in 2005 in an international sales effectiveness role and has since held operational leadership roles with increasing responsibilities in Italy, Spain and at corporate headquarters. Prior to this, Mr Helfgott was with McKinsey & Company in Paris, Moscow and Brussels from 1998 to 2005.

Mr Helfgott serves as president of the Novo Nordisk Haemophilia Foundation (NNHF) council.

  • 2001: MBA, INSEAD, France.
  • 1998: Graduate of the French Army Officer’s Academy, E.A.A.B.C, France.
  • 1996: MA in Finance & Laureate of the Health Economy Chair, E.S.S.E.C, France.
  • 1994: MA in Political and Macroeconomy, I.E.P. Paris, France.

Mr Helfgott is a French national, born July 1974.